Oskar Ljungquist

Medicin och livsvetenskap

1. Sweden 100%
2. beta-Lactamases 68%
3. Enterobacteriaceae 47%
4. Bacteremia 43%
5. Observational Studies 36%
6. 16S Ribosomal RNA 31%
7. Pleural Empyema 30%
8. galantide 30%
9. Randomized Controlled Trials 28%
10. Infections 28%
11. Acinetobacter 26%
12. Cephalosporins 26%
13. Carbapenems 24%
14. Probiotics 22%
15. Mortality 21%
16. Cohort Studies 19%
17. Escherichia coli 19%
18. Prostate 17%
19. Diarrhea 17%
20. Placebos 17%
21. Standard of Care 17%
22. Cross-Sectional Studies 16%
23. Immunoglobulin G 16%
24. Meta-Analysis 16%
25. Systematic Reviews 15%
26. Dogs 15%
27. Transplants 13%
28. Biopsy 13%
29. Blood Vessels 12%
30. Therapeutics 12%
31. Antibodies 11%
32. Blood Culture 11%
33. Extraintestinal Pathogenic Escherichia coli 11%
34. Aneurysm 11%
35. Population 10%
36. Immunosuppression 10%
37. Urinary Tract Infections 10%
38. Uropathogenic Escherichia coli 10%
39. Viridans Streptococci 10%
40. Anaerobic Bacteria 8%
41. Whole Genome Sequencing 8%
42. Anti-Bacterial Agents 7%
43. fim 1 7%
44. Oxygen 7%
45. Ciprofloxacin 7%
46. Genes 7%
47. Streptococcus pneumoniae 7%
48. Acinetobacter Infections 6%
49. Convalescent Hospital 5%
50. beta-lactamase CTX-M-15 5%